Gestational ovarian choriocarcinoma

Summary

Gestational ovarian choriocarcinoma (MONDO:0004294) is a disease. A subtype of choriocarcinoma of ovary — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gestational ovarian choriocarcinoma
Mondo ID	MONDO:0004294
DOID	DOID:7591
NCIT	C40442
UMLS	C1517538
MedGen	274586
GARD	0023917
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: gestational ovarian choriocarcinoma

Disease family

This is a subtype of choriocarcinoma of ovary. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › trophoblastic neoplasm › choriocarcinoma › choriocarcinoma of ovary › gestational ovarian choriocarcinoma

Related subtypes (1): non-gestational ovarian choriocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.